Clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury: A Meta-analysis of randomized controlled trials

Tao LiNa; Qu XiaoYu; Zhang Yue; Song YanQing; Zhang SiXi

doi:10.3969/j.issn.1001-5256.2019.08.025

Volume 35 Issue 8

Aug. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(8): 1775-1781

PDF( 2367 KB)

Clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury: A Meta-analysis of randomized controlled trials

DOI: 10.3969/j.issn.1001-5256.2019.08.025

Department of Pharmacy, The First Hospital of Jilin University

Research funding:

Received Date: 2019-06-19
Published Date: 2019-08-20

Abstract

Abstract

Objective To evaluate the clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury (ATB-DILI) , since there have always been controversies over the development of Silybum marianum preparation for the prophylactic treatment of ATB-DILI. Methods MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) on Silybum marianum preparation versus placebo in preventing ATB-DILI published up to November 30, 2018. STATA 12. 0 software was used for statistical analyses. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CI) were used to evaluate the effect of Silybum marianum preparation. The Cochrane handbook was used to assess the quality of RCTs, and funnel plots and Egger's tests were used to evaluate publication bias. A sensitivity analysis was conducted to assess the influence of each RCT on overall effect. Results A total of five RCTs with 1198 patients were included, and among these patients, 585 received Silybum marianum preparation and 613 received placebo. Silybum marianum preparation significantly reduced the risk of the onset of ATB-DILI at week 4 (RR = 0. 33, 95% CI: 0. 15-0. 75, P = 0. 008) . In addition, Silybum marianum preparation had a protective effect on liver function in patients receiving antitubercular agents (alanine aminotransferase: SMD =-0. 15, 95% CI:-0. 24 to-0. 07, P < 0. 001; aspartate aminotransferase: SMD =-0. 14, 95% CI:-0. 23 to-0. 06, P = 0. 001; alkaline phosphatase: SMD =-0. 12, 95% CI:-0. 20 to-0. 03, P = 0. 008) . Silybum marianum preparation had a similar risk of adverse events as placebo (RR = 1. 09, 95%CI: 0. 86-1. 39, P = 0. 47) . Conclusion In patients with tuberculosis, prophylactic treatment with Silybum marianum preparation can significantly reduce the risk of the onset of ATB-DILI after 4 weeks of treatment. In addition, Silybum marianum preparation can also improve the liver function of patients treated with antitubercular agents.
- chemical and drug induced liver injury,
- antitubercular agents,
- silymarin,
- Meta-analysis as topic

FullText(HTML)

References(51)

References

[1] World Health Organization. Global tuberculosis report 2017[EB/OL]. Geneva:WHO, 2017.

[2] HORSBURGH CR Jr, BARRY CE 3rd, LANGE C. Treatment of tuberculosis[J]. N Engl J Med, 2015, 373 (22) :2149-2160.

[3] WU S, XIA Y, LV X, et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients[J]. J Gastroenterol Hepatol, 2015, 30 (3) :540-545.

[4] TOSTMANN A, BOEREE MJ, AARNOUTSE RE, et al. Antituberculosis drug-induced hepatotoxicity:Concise up-to-date review[J]. J Gastroenterol Hepatol, 2008, 23 (2) :192-202.

[5] SAUKKONEN JJ, COHN DL, JASMER RM, et al. An official ATS statement:Hepatotoxicity of antituberculosis therapy[J].Am J Respir Crit Care Med, 2006, 174 (8) :935-952.

[6] METUSHI I, UETRECHT J, PHILLIPS E. Mechanism of isoniazid-induced hepatotoxicity:Then and now[J]. Br J Clin Pharmacol, 2016, 81 (6) :1030-1036.

[7] BASKARAN UL, SABINA EP. Clinical and experimental research in antituberculosis drug-induced hepatotoxicity:A review[J]. J Integr Med, 2017, 15 (1) :27-36.

[8] HACKETT ES, TWEDT DC, GUSTAFSON DL. Milk thistle and its derivative compounds:A review of opportunities for treatment of liver disease[J]. J Vet Intern Med, 2013, 27 (1) :10-16.

[9] KIDD PM. Bioavailability and activity of phytosome complexes from botanical polyphenols:The silymarin, curcumin, green tea, and grape seed extracts[J]. Altern Med Rev, 2009, 14 (3) :226-246.

[10] LEE JI, NARAYAN M, BARRETT JS. Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 845 (1) :95-103.

[11] SHERIF IO, AL-GAYYAR MM. Antioxidant, anti-inflammatory and hepatoprotective effects of silymarin on hepatic dysfunction induced by sodium nitrite[J]. Eur Cytokine Netw, 2013, 24 (3) :114-121.

[12] KARIMI G, VAHABZADEH M, LARI P, et al. Silymarin, a promising pharmacological agent for treatment of diseases[J]. Iran J Basic Med Sci, 2011, 14 (4) :308-317.

[13] AU AY, HASENWINKEL JM, FRONDOZA CG. Hepatoprotective effects of S-adenosylmethionine and silybin on canine hepatocytes in vitro[J]. J Anim Physiol Anim Nutr (Berl) , 2013, 97 (2) :331-341.

[14] SINGH M, SASI P, GUPTA VH, et al. Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model[J]. Hum Exp Toxicol, 2012, 31 (8) :788-797.

[15] EMINZADE S, URAZ F, IZZETTIN FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals[J]. Nutr Metab (Lond) , 2008, 5 (1) :18.

[16] MANN A, PELZ T, RENNERT K, et al. Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance[J]. Hum Cell, 2017, 30 (4) :267-278.

[17] ABENAVOLI L, CAPASSO R, MILIC N, et al. Milk thistle in liver diseases:Past, present, future[J]. Phytother Res, 2010, 24 (10) :1423-1432.

[18] LIU Q, GARNER P, WANG Y, et al. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy:Systematic review of ingredients and evaluation studies[J]. BMC Public Health, 2008, 8:365-372.

[19] LUANGCHOSIRI C, THAKKINSTIAN A, CHITPHUK S, et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J].BMC Complement Altern Med, 2015, 15 (1) :334.

[20] MARJANI M, BAGHAEI P, KAZEMPOUR DIZAJI M, et al.Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients:A randomized clinical trial[J]. Iran J Pharm Res, 2016, 15 (1) :247-252.

[21] ZHANG S, PAN H, PENG X, et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury:A randomized controlled trial[J]. J Gastroenterol Hepatol, 2016, 31 (2) :409-416.

[22] KNOBLOCH K, YOON U, VOGT PM, et al. Preferred reporting items for systematic reviews and Meta-analyses (PRISMA) statement and publication bias[J]. J Craniomaxillofac Surg, 2011, 39 (2) :91-92.

[23] HIGGINS J. Cochrane handbook for systematic reviews of interventions version 5. 1. 0[EB/OL]. (2011-03) . The Cochrane Collaboration, 2011. http://handbook. cochrane.org/.

[24] WAN X, WANG WQ, LIU JM, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range[J]. BMC Med Res Methodol, 2014, 14 (1) :135.

[25] RAMANATHAN R, SIVANESAN K. Evaluation of ameliorative ability of Silibinin against zidovudine and isoniazid-induced hepatotoxicity and hyperlipidaemia in rats:Role of Silibinin in Phase I and II drug metabolism[J]. Chem Biol Interact, 2017, 273:142-153.

[26] GHOSH K, INDRA N, JAGADEESAN G. The ameliorating effect of centella asiatica ethanolic extract on albino rats treated with isoniazid[J]. J Basic Clin Physiol Pharmacol, 2017, 28 (1) :67-77.

[27] MARTIN SJ, SABINA EP. Amelioration of anti-tuberculosis drug induced oxidative stress in kidneys by spirulina fusiformis in a rat model[J]. Ren Fail, 2016, 38 (7) :1115-1121.

[28] EVAN PRINCE S, UDHAYA LB, SUNITHA PS, et al. Reparation of isoniazid and rifampicin combinatorial therapy-induced hepatotoxic effects by bacopa monnieri[J]. Pharmacology, 2016, 98 (1-2) :29-34.

[29] MARTIN SJ, BASKARAN UL, VEDI M, et al. Attenuation of anti-tuberculosis therapy induced hepatotoxicity by Spirulina fusiformis, a candidate food supplement[J]. Toxicol Mech Methods, 2014, 24 (8) :584-592.

[30] SRIVASTAVA RK, SHARMA S, VERMA S, et al. Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats[J]. Methods Find Exp Clin Pharmacol, 2008, 30 (10) :731-737.

[31] WU JW, TSAI TH. Effect of silibinin on the pharmacokinetics of pyrazinamide and pyrazinoic acid in rats[J]. Drug Metab Dispos, 2007, 35 (9) :1603-1610.

[32] TASDUQ SA, PEERZADA K, KOUL S, et al. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin[J]. Hepatol Res, 2005, 31 (3) :132-135.

[33] OOSTHUIZEN C, ARBACH M, MEYER D, et al. Diallyl polysulfides from allium sativum as immunomodulators, hepatoprotectors, and antimycobacterial agents[J]. J Med Food, 2017, 20 (7) :685-690.

[34] CRONJL, EDMONDSON N, EISENACH KD, et al. Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions[J].FEMS Immunol Med Microbiol, 2005, 45 (2) :103-112.

[35] CHAN MK, CHAN PC, WONG KK, et al. Hepatitis B infection and renal transplantation:The absence of anti-delta antibodies and the possible beneficial effect of silymarin during acute episodes of hepatic dysfunction[J]. Nephrol Dial Transplant, 1989, 4 (4) :297-301.

[36] KATAOKA K, KONO Y, SUGIMOTO M, et al. Hepatocyteprotective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder[J].Exp Ther Med, 2010, 1 (6) :1041-1047.

[37] CHENG S. To research the antiviral treatment of low grade chronic hepatitis B associated with tuberculosis patients (82 cases contrast analysis) [C]. Hepatology international conference:26th annual conference of the Asian Pacific Association for the Study of the Liver, China, 2017.

[38] BEDI S, GOEL A, CHAND N, et al. A prospective study for evaluating the effect of silymarin on hepatic functions in tubercular patients receiving dots[J]. Chest, 2009, 136:74S.

[39] CHENG S. The efficacy of silymarin on the prevention of hepatotoxicity from antituberculosis drugs[J]. Gastroenterology, 144 (5 Suppl 1) :s993.

[40] Clinicaltrials. gov. Effect of prophylactic use of silymarin on hepatotoxicity induced by anti-tuberculosis drugs (PESOHHERZ) [EB/OL].[2017-11-30]. https://clinicaltrials.gov/ct2/show/NCT01436929? term=silymarin&cond=tuberculosis&rank=1.

[41] LI J, LIN WF, PAN YY, et al. Protective effect of silibinin on liver injury induced by antituberculosis drugs[J]. Chin J Hepatol, 2010, 18 (5) :385-386.

[42] HU Z, YANG X, HO PC, et al. Herb-drug interactions:A literature review[J]. Drugs, 2005, 65 (9) :1239-1282.

[43] GU J, TANG SJ, TAN SY, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury[J]. Int J Clin Exp Med, 2015, 8 (3) :4320-4327.

[44] HEO E, KIM DK, OH SH, et al. Effect of prophylactic use of silymarin on anti-tuberculosis drugs induced hepatotoxicity[J]. Tuberc Respir Dis (Seoul) , 2017, 80 (3) :265-269.

[45] RAMAPPA V, AITHAL GP. Hepatotoxicity related to anti-tuberculosis drugs:Mechanisms and management[J]. J Clin Exp Hepatol, 2013, 3 (1) :37-49.

[46] LEE CM, LEE SS, LEE JM, et al. Early monitoring for detection of antituberculous drug-induced hepatotoxicity[J]. Korean J Intern Med, 2016, 31 (1) :65-72.

[47] METUSHI IG, ZHU X, CHEN X, et al. Mild isoniazid-induced liver injury in humans is associated with an increase in Th17cells and T cells producing IL-10[J]. Chem Res Toxicol, 2014, 27 (4) :683-689.

[48] METUSHIIG, CAI P, ZHU X, et al. A fresh look at the mechanism of isoniazid-induced hepatotoxicity[J]. Clin Pharmacol Ther, 2011, 89 (6) :911-914.

[49] SU M, CHEN H, WEI C, et al. Potential protection of vitamin C against liver-lesioned mice[J]. Int Immunopharmacol, 2014, 22 (2) :492-497.

[50] ABENAVOLI L, IZZO AA, MILIC'N, et al. Milk thistle (Silybum marianum) :A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases[J]. Phytother Res, 2018, 32 (11) :2202-2213.

[51] ABOUZID SF, AHMED HS, ABD EL, et al. Linear regression analysis of silychristin A, silybin A and silybin B contents in Silybum marianum[J]. Nat Prod Res, 2018.[Epub ahead of print]

Relative Articles

[1]	Xin DAI, Hanlin LIU, Long CHENG, Zhulin LUO, Tao WANG. Association of programmed death-1 and programmed death-ligand 1 with the prognosis and clinical features of patients with hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2022.07.022
[2]	Liangliang GAN, Jinzhou ZHANG, Xiandong WANG, Caihong FU, Jia SU, Xuemei TANG. Efficacy of artificial liver support system in treatment of acute-on-chronic liver failure: A network Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(1): 135-140. doi: 10.3969/j.issn.1001-5256.2022.01.021
[3]	Xin DAI, Hanlin LIU, Qiang WANG, Peng SHU, Long CHENG, Tao WANG. Short-term efficacy and safety of Da Vinci robotic pancreaticoduodenectomy versus traditional laparoscopic pancreaticoduodenectomy: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1106-1113. doi: 10.3969/j.issn.1001-5256.2022.05.025
[4]	Zhiran YANG, Linheng WANG, Yuan LI, Fusheng LIU, Yu WANG, Jianfang WANG, Runhua CHEN. Diagnostic value of transient elastography in the staging of hepatic fibrosis in patients with autoimmune liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(1): 97-103. doi: 10.3969/j.issn.1001-5256.2022.01.015
[5]	Fei LIU, Hai LI, Qiang WU. Risk factors for bile leakage after hepatectomy without biliary reconstruction: A Meta - analysis[J]. Journal of Clinical Hepatology, 2022, 38(3): 594-600. doi: 10.3969/j.issn.1001-5256.2022.03.019
[6]	Ying LIU, Benjian GAO, Xiaoli YANG, Cheng FANG, Song SU, Bo LI. Effect of hemihepatic vascular exclusion versus total hepatic vascular exclusion in hepatectomy for primary liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(1): 73-78. doi: 10.3969/j.issn.1001-5256.2021.01.015
[7]	Quan ZHOU, Lihui YANG, Fangqing JIANG. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1836-1840. doi: 10.3969/j.issn.1001-5256.2021.08.018
[8]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[9]	Tingpeng HU, Sudan TANG, Zebo YU. Relationship between vitamin D level in children and adolescents with nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(3): 627-631. doi: 10.3969/j.issn.1001-5256.2021.03.024
[10]	Shun ZHU, Zhiguo LI, Shuo LI, Xu CAO, Xiaobin LI, Xiaoke LI, Yongan YE. Effect of aspirin on the incidence rate of liver cancer in patients with viral hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1097-1102. doi: 10.3969/j.issn.1001-5256.2021.05.024
[11]	Deliang HUANG, Wei DAI, Jun CHEN, Xiaoguang YE. Clinical features of liver injury induced by anti-tuberculosis drugs and related risk factors[J]. Journal of Clinical Hepatology, 2021, 37(10): 2369-2375. doi: 10.3969/j.issn.1001-5256.2021.10.022
[12]	Sun DongXue, Yang Zhu, Long FengXi, Wei XianMan, Tang DongXin. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 363-368. doi: 10.3969/j.issn.1001-5256.2020.02.026
[13]	Liu ShenShen, Xing YiQing, Wang Ning, Yu QiaoLing, Ceng LePing. Clinical effect of vitamin E in treatment of nonalcoholic fatty liver disease in children: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1545-1550. doi: 10.3969/j.issn.1001-5256.2020.07.019
[14]	Wang XiangHong, Ma BaoHua, Zou XiuLan, Yao KeCheng, He Qian. Association between nonalcoholic fatty liver disease and epicardial adipose tissue: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(6): 1304-1309. doi: 10.3969/j.issn.1001-5256.2020.06.023
[15]	Tian Bing, Li Fan, Deng BaoCheng. Clinical effect of artificial liver support system in treatment of drug-induced liver failure: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(4): 823-828. doi: 10.3969/j.issn.1001-5256.2020.04.023
[16]	Qian Le, Ying Li. Selection of second-line drugs for adult autoimmune hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2015-2020. doi: 10.3969/j.issn.1001-5256.2020.09.021
[17]	Lai Li, Peng FangYi, Su Song, Fang Cheng, Zhang MengYu, He Kai, Li Bo, He Pan, Xia XianMing. Clinical effect of robotic versus laparoscopic splenectomy in treatment of nontraumatic splenic diseases:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2281-2285. doi: 10.3969/j.issn.1001-5256.2019.10.030
[18]	Sun Ying, Li RunPu, Wang XiaoJie. Correlation between liver damage degree and clinical manifestations in patients with pulmonary tuberculosis after chemotherapy[J]. Journal of Clinical Hepatology, 2015, 31(7): 1110-1113. doi: 10.3969/j.issn.1001-5256.2015.07.027
[19]	Zhang MingYuan, Lei JianPing, Yan ShiMing, Zhang WenHong, Huang YiXin, Niu JunQi. Liver injury induced by anti-tuberculosis drugs and anti-tuberculosis therapy for patients with liver disease: introduction of the experience of diagnosis and treatment in Chinese mainland and “Taiwan Guidelines for TB Diagnosis & Treatment”[J]. Journal of Clinical Hepatology, 2015, 31(11): 1776-1781. doi: 10.3969/j.issn.1001-5256.2015.11.004
[20]	Shen ShuiYing, Wu Jun. Acute liver failure caused by antitubercular drugs: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(9): 1483-1484. doi: 10.3969/j.issn.1001-5256.2015.09.029

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	许俊翱，黄艳雯，金满春. 水飞蓟素治疗临床肝病的疗效和不良反应分析. 系统医学. 2024(20): 66-69 .
2.	万丽红，张静，陈爽，赵萍. 替诺福韦酯联合复方益肝灵片对肺结核合并HBV携带患者免疫功能及肝肾功能的影响. 临床和实验医学杂志. 2023(18): 1938-1942 .
3.	管斌，朱建荣. 水飞蓟宾预防抗结核药物所致肝损伤的效果及安全性Meta分析. 中国热带医学. 2021(05): 496-500 .
4.	赵红，吕芳芳，桑荣霞，王晓忠，李志惠，谢雯. 水飞蓟宾胶囊治疗药物性肝损伤的临床疗效. 甘肃医药. 2021(06): 490-493 .
5.	金小琳，杨智彬，詹淑华，朱丹，何海英，殷水泽，马世武. 1501例初治住院结核病患者肝功能异常的影响因素. 中华实验和临床感染病杂志(电子版). 2020(05): 394-400 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1891) PDF downloads(272)

Clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury: A Meta-analysis of randomized controlled trials

DOI: 10.3969/j.issn.1001-5256.2019.08.025